ROCKVILLE, Md., Aug. 10, 2018 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced the pricing of an underwritten public
offering of 2,700,000 shares of its common stock at the price
of $65.00 per share before
underwriting discounts and commissions. The gross proceeds to
REGENXBIO from the offering, before deducting the underwriting
discounts and commissions and other offering expenses payable by
REGENXBIO, are expected to be $175.5
million. This offering is expected to close on August 14, 2018, subject to customary closing
conditions. Additionally, REGENXBIO has granted the underwriters a
30-day option to purchase an additional 405,000 shares of
common stock at the public offering price, less underwriting
discounts and commissions.
Morgan Stanley, BofA Merrill Lynch and Barclays are acting as
joint book-running managers. Raymond
James is acting as co-manager of the offering.
The securities described above are being offered by REGENXBIO
pursuant to a shelf registration statement on Form S-3 that was
filed with the Securities and Exchange Commission (the "SEC") on
August 8, 2018, which became
automatically effective upon filing. A preliminary prospectus
supplement relating to and describing the terms of the offering was
filed with the SEC and is available on the SEC's website at
www.sec.gov. Copies of the final prospectus supplement and the
accompanying prospectus relating to this offering, when available,
may be obtained from: Morgan Stanley at Attention: Prospectus
Department, 180 Varick Street, 2nd Floor, New York, NY, 10014; BofA Merrill Lynch at
NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention:
Prospectus Department or by email at
dg.prospectus_requests@baml.com; or Barclays Capital Inc., c/o
Broadridge Financial Solutions, at 1155 Long Island Avenue,
Edgewood, New York 11717 or by
email at barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy any of these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the applicable securities
laws of such state or jurisdiction.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Forward-Looking Statements
This press release includes "forward-looking statements," within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements express a belief, expectation or
intention and are generally accompanied by words that convey
projected future events or outcomes such as "believe," "may,"
"will," "estimate," "continue," "anticipate," "design," "intend,"
"expect," "could," "plan," "potential," "predict," "seek,"
"should," "would" or by variations of such words or by similar
expressions. The forward-looking statements include statements
relating to, among other things, REGENXBIO's proposed offering of
its common stock. REGENXBIO has based these forward-looking
statements on its current expectations and assumptions as well as
other factors REGENXBIO believes are appropriate under the
circumstances. However, whether actual results and developments
will conform with REGENXBIO's expectations and predictions is
subject to a number of risks and uncertainties, many of which are
beyond the control of REGENXBIO. For a discussion of these risks,
refer to the "Risk Factors" and "Management's Discussion and
Analysis of Financial Condition and Results of Operations" sections
of REGENXBIO's Annual Report on Form 10-K for the year ended
December 31, 2017 and Quarterly
Report on Form 10-Q for the quarter ended June 30, 2018 and other filings with the SEC,
which are available on the SEC's website at www.sec.gov. All of the
forward-looking statements made in this press release are expressly
qualified by the cautionary statements contained or referred to
herein. The actual results or developments anticipated may not be
realized or, even if substantially realized, they may not have the
expected consequences to or effects on REGENXBIO or its businesses
or operations. Such statements are not guarantees of future
performance and actual results or developments may differ
materially from those projected in the forward-looking statements.
Readers are cautioned not to rely too heavily on the
forward-looking statements contained in this press release. These
forward-looking statements speak only as of the date of this press
release. REGENXBIO does not undertake any obligation, and
specifically declines any obligation, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investors
Natalie
Wildenradt, 646-681-8192
natalie@argotpartners.com
Media
Adam Pawluk,
202-591-4063
apawluk@jpa.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-pricing-of-public-offering-of-common-stock-300695232.html
SOURCE REGENXBIO Inc.